Hans H.
- Country
- Denmark
- Department
- Hæmatologisk afdeling
Research Overview
- Evaluation of Peginterferon Alfa-2a and Ruxolitinib Combination Therapy in Newly Diagnosed Polycythemia Vera Patients: A Danish Safety and Efficacy Study
- Evaluation of Atorvastatin as an Adjuvant Therapy in Philadelphia-Negative Myeloproliferative Neoplasms: Impact on Inflammatory Markers and Cell Counts
Data & Insights
Has run more than one trial at 1 of 1 partner site.
Specializations
Myeloproliferative Disorders
The investigator specializes in treating Polycythemia Vera and explores innovative therapeutic approaches, including combination treatments with interferon-alpha2a and targeted therapies.
- Blood disorder management
- Therapeutic combinations
- Disease control strategies
Their work extends to evaluating safety profiles in newly diagnosed patients.
Hematologic Malignancies
Focusing on Philadelphia-negative chronic myeloproliferative neoplasms, the investigator studies treatment approaches incorporating atorvastatin alongside conventional therapies.
- Blood cancer treatments
- Inflammatory markers
- Cell count analysis
Their research includes evaluation of adjuvant treatment effects in blood disorders.
Thrombocythemia Research
The investigator conducts comparative studies in Essential Thrombocythemia treatment, examining various therapeutic agents including bomedemstat and established treatments.
- Platelet disorder management
- Treatment comparison studies
- Clinical response assessment
Their work aims to advance treatment options for thrombocythemia patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.